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388A ABSTRACTS - Myocardial Ischemia and Infarction 
tiveness of monteplase admlnistration prior to emergent PCI in AMI. METHOD: Out of 
243 consecutive AMI from 1998 to 2002. we enrolled into the COMA trial 108 patients 
who were under 75 years of age and had been admitted within 12 hrs after the onset of 
AMI. Patients were randomly assigned to receive direct PCI (group P, n=57) or PCI fol- 
lowed by pretreatment with intravenous monteplase (27500 IU/kg. group M, 1x51). 
RESULTS: Primary endpoint of this trial was left ventricular function (EF) at 6 months fol- 
low-up. In the initial CAG before PCI, TIMI- flow was obtained in 29% of group M, but in 
only 7% of group P (P=O.O02). There was no significant difference in the PCI success 
rate, major cardiac or bleeding complications in both groups. No-reflow phenomenon in 
group P was obselved more frequently than group M (17.5% vs 4.4%. P=O.O4). There 
were no significant differences EF in both groups. Thus, we divided the group M into sub- 
groups according to whether or not TIMI- flow was obsewd at initial CAG. In the group 
M with TIMI- flow, LVEDVI was smaller and the EF was greater than Group P (SS.O+/- 
1.8 vs 5&6+/-l .4, P=O.O02). QCA results showed that the mlnimal lumen diameter was 
larger in the monteplase group M immediately after PCI, and the difference was even 
greater at 6 months. CONCLUSION: Intravenous Injection of monteplase can promote 
rapid repertusion and appears to maintain LV function, to suppress LV remodeling and 
late restenosis. We propose a combination therapy of PCI with monteplase injection in 
order to achieve reperfusion as early as possible, 
1191-29 Angiographic Predictors of Left Ventricular Ejection 
Fraction After Successful Angioplasty in Acute 
Myocardial Infarction: An Angiographic Risk Score for 
Use in the Catheterization Laboratory 
Jose P. Henriaues. Felix Zijlstra. Jan-Paul Ottewanger, Jan-Henk E. Dambrink, Arnoud 
W. van ‘t Hof, Jan C. Hoorntje, Menko-Jan de Boer, Harry Suryapranata. lsala Klinieken, 
Locatie Weezenlanden, Zwolle, The Netherlands 
Background: We investigated the value of coronary angiographic parameters in patients 
with successful primary angioplasty to predict left ventricular function and 30 day mortal- 
ity. using a simple angiographic risk score. 
Methods: In 608 consecutive patients with successful primary angloplasty, we assessed 
the infarct related artery, antegrade flow before treatment, presence of distal embolisa- 
tion and myocardial blush grade on the coronary angiogram made immediately after cor- 
Onaly angioplasty. Endpoints were death after 30 days and left ventricular ejection 
fraction. 
Results: A simple risk score was conceived attributing points to predictive variables. Mul- 
tivariate analysis revealed that LAD related infarction (OR 8.4, CI:5.4-13.1, pcO.001: 3 
points), TIMI O-2 flow before angloplasty (OR 2.2, Cl:1 .l-4.2, pcO.02: 1 point), myocardial 
blush 0 or 1 (OR 2.5, Cl: 1.2-5.1. p=O.Ol; 1 point) and distal embolisation (2.2, Cl:1 .I-4.2, 
p=O.O2; 1 point) were independent predictors of left ventricular ejection fraction ~40% 
after successful angioplasty Using this score (0 to 6 points), residual left ventricular ejec- 
tion fraction and 30 day mortality can be predicted. Patients with 0 or 1 point had an ejec- 
tion fraction of 49.5% * 6.4 and a 30 day mortality of 0.8%. Patients with a score of 2 or 3 
had an ejection fraction of 44.9% * 10.3 and a 30 day mortality of 2.8%. whereas 
patients with a score of 4 had an ejection fraction of 36.2% f 10.8 and a 30 day mortaltty 
of 2.7%. Patients with a score of 5 or 6 had an ejection fraction of 32.0% + 9.4 and a 30 
days mortality of 6.9% (p for trend co.01 for mortality and ~0.001 for ejection fraction). 
Conclusions: Successful angioplasty for acute myocardial infarction leads to a good clin- 
ical outcome. However, a simple angiographic score based on 4 angiographic parame- 
ters can further predict ejection fraction and mortality when leaving the catheterization 
laboratory in pabents with successful reperfusion by primary angioplasty for acute myo- 
cardial infarction. 
1191-30 The Vaeopeptidase Inhibitor, Omapatrilat, Increases 
Survival, Improves Cardiac Function, and Attenuates 
Ventricular Remodeling After Coronary Artery Ligation 
in Insulin Resistant Zucker Fatty Rats 
Nathalie Lapolnte. Quang Trinh Nguyen, Francois Marcotte, Fayez Dawood, Peter Liu, 
Albert Adam, Jean-Lucien Rouleau. Toronto General Hospital, Toronto, ON, Canada 
Background: Vasopeptidase inhibitors (VPl’s) block both angiotensin converting 
enzyme and neutral endopeptidase. By reducing angiotensin II and enhancing endoge- 
nous vasodilators substances, VPl’s may be particularly beneficial in situation where an 
imbalance in favour of vasoconstrictor substances occurs, such as in insulin resistance 
and peri and post myocardial infarction (Ml). 
Methods: Ml was induced in 154 male Zucker fatty rats by ligating the left anterior coro- 
nary artery. Rats were untreated or pretreated 7 days with omapatrilat IO mg/kg/day. 
Post Ml (30 days), an echocardiogram was done and at 38 days hemodynamic measure- 
ments were performed, the rats scarified, and morphologic measurements done. A large 
Ml was defined as an infarct size> 35 rn& and a moderate MI was defined as an infarct 
size t 35 mrr?. 
Results: Omapatrilat normalized blood glucose and resulted in a better early (24h) sur- 
vival post MI (63% vs 41%. p=O.O03) that was maintained for 38 days, the time of sacri- 
fice (35% vs 22%, p=O.Ol). Omapatrilat reduced the number of rats with a large Ml as 
compared with untreated, an effect that presumably occurred during the first few hours 
post MI. Long term (38 days), omapatrilat resulted in beneficial ventricular remodeling as 
reflected by a reduction in left ventricular (LV) diastolic (1 .12cm for omapatrilat vs 1.02cm 
for untreated, p=O.OOl) and systolic (1.02cm for omapatrilat vs 0.89cm for untreated, 
p=O.O3) circumference by echocardiography in large Ml as compared with untreated. 
This resulted in hemodynamic improvement, and a decrease in LV and pulmonary weight 
indicating a decrease in reactive hypertrophy and pulmonary congestion at the time of 
sacrifice. Conclusion: This study indicates that pre treatment with the VPI omapatrilat 
increases early (24 hour) post-MI survival in insulin reslstant rats by reducing Ml size. 
This improvement is sustained over a 38 day follow-up and accompanied by normaliza- 
tion of blood glucose, improvement of LV remodeling and hemodynamic parameters. 
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1191-45 Clinical Pathway Improves Acute Myocardial Infarction 
Quality Indicators 
Jeb Burchenal, Megan Brewer, Marianne McCollum, Kathleen A. Stringer, University of 
Colorado Health Sciences Center, Denver, CO 
Despite published guidelines, the majority of patients with acute Ml still do not achieve 
the goals of door-to-balloon time (DtB) 90+/-30min or appropriate drug utilization. We 
hypothesized that a clinical pathway could increase compliance with treatment guide- 
lines. To determine the impact of a clinical Ml pathway on quality Indicators, two cohorts 
of patients undergoing primary PTCA for acute Ml were identified (control group n = 89 
and intewention group n = 66). The medical records of the control group (1998.99) were 
reviewed for DtB and ASA, beta-blocker (BE), ACE inhibitor (ACEI), and lipid lowering 
therapy use and compared to the prospective data of the intervention group (2000-01). 
The impact of the pathway was evaluated using the Wilcoxon Rank Sum Test, odds 
ratios and Chi Square tests. DtB was significantly lower in the intervention group (91.5 vs 
108 min., p<O.Ol). The intervention group had fewer patients exceeding the guidelwws 
wtth a DtB > 120 min (OR = 0.38, p < 0.01). The intervention group was more likely to 
have an ACEI (OR = 3.7, p < 0.01) or lipid lowering therapy (OR = 3.7, p = 0.02) at dis- 
charge compared with the control group (figure). ASA and BB use was appropriate and 
was not different (ASA: 95.2% vs 96.2%; BB: 93.5% vs 92.6%). These data suggest that 
in the current era of published treatment guidelines, implementation of a clinical pathway 
can still improve Ml quality indicators and further improve clinical care. 
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1191-46 Which Is the Best Streptokinase Regimen in ST Acute 
Myocardial Infarction? A Prospective Study 
Gabriel Tatu-Chitoiu, Cristina Teodorescu, Monica Dan, Manuela Guran, Petre Capraru, 
Alexandrina Tatu-Chitoiu. Aurelia Bumbu. Maria Dorobantu, Spit&l Clinic de Urgenta, 
Bucuresti, Romania. Spit&l “Victor Babes”, Bucuresti. Romania 
Objective. In a prospective study we compared the safety and efficacy of three Streptoki- 
nase regimens: 1. Infusion of 1.5 M.U./60 min (the SKI .5/60 regimen). 2. Infusion of 1.5 
MU/20 min (the SKl.5/20 regimen). 3. Bolus of 0.75 M.U./lO min repeated after 50 min. 
only if no signs of coronary reperfusion have been detected (the SK 0.75/10 regimen) in 
pts. with ST acute myocardial infarction (STAMI). 
Methods. A group of 849 patients admitted within the first 6 hours after the onset of the 
chest pain revealing STAMI) have been divided in 3 subgroups according to the throm- 
bolytic regimen used: SKl.5/60 (306 pts.), SK1.5/20 min. (349 pts.) and SK0.75 MU/10 
min. (195 pts.). All pts received heparin (1000 i.u./hour, 48-72 hours) and aspirin.. Three 
noninvasive reperfusion criteria have been used: 1 .Rapid resolution of the chest pain. 
P.Rapid decreasing of the ST segment elevations by more than 50% from the initial 
value. 3.Rapid increasing of the CK and CK-MB with a peak within the first 12 hrs. The 
incidence of haemorrhagic events, the ratio of coronary reperfusion, and the in hospital 
mortality were evaluated. 
Results. The ratios of the coronary repelfusion were 73.3% in the SKI.5120 and 73.8% in 
the SK0.7500 sbgroup. These ratios were equal each other but significant higher that 
the one of 61.7% registered in the SKI .5/60 min. subgroup. (p=O.O02 and 0.015, respec- 
tivelv). In ots. vounaer than 75 the 30 dav mortalitv was 5.59% (SKl.5/20), 5.38% 
(SK6:75/10) and 114% (SKl.5/60) (1.5/2d “s 1.5/60 p= 0.008; 0.75/10 Y; 1.5120 
o=O.O29). One oatient in the SKI .5/60 suborouo had sians of ischemic stroke. The inci- 
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dence of the major haemorrhagic events were 2.94% (SK1.5/60), 0.85% (SKl.5/20) and 
0.0% (SK0.75/10) (non-significant differences) 
Conclusions. Two accelerated SK regimens (SK1.5120 and 0.75110) are safe, equally 
efficient and lead toward a significant higher ratio of coronary reperfusion and a signifi- 
cant lower mortality as compared to the classical SK1.5/60 one in pts. younger that 75. 
1191-47 Influence of Biochemical Markers on Thrombolysis 
Effectiveness Early in the Course of ST-Segment 
Elevation Myocardial Infarction 
Michael N. &iris. Olga Papadaki. Paraskevi Psarogianni, Anastassios Lyras. George 
Psaltiras, Stavros Manousakis. Pelagia Batika. Demetrios Beldekos. Evdokta 
Adamopoulou, Apostolos Papantonakos, Spyros Argyrakis. Stefanos Foussas, Tzanio 
Hospital, Plraeus, Greece 
Background: Whilst the benefit of intravenous thrombolysis (IT) in ST-segment eleva- 
tion myocardial infarction (STEMI) is unequivocal, rep&t&ion fails in many pts. The aim 
of this was to evaluate the role of plasma levels of either high sensitivity C-reactive pro- 
tein (hs-CRP), cardiac troponin I (cTnl), lipoprotein (a) Lp(a), or fibrinogen (Fb) on IT 
